Skip to main content
SpringerLink
Log in

Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on Sorafenib

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Worldwide progressive population aging demands consensus development for decision making when treating elderly patients. Age itself might not be a critical determinant for the selection of a therapeutic option. In the past few years, the mechanisms of hepato-carcinogenesis have been elucidated, and the involvement of a number of pathways, including angiogenesis, aberrant signal transduction, and dysregulated cell cycle control, have been demonstrated, leading to evaluation of the activity and toxicity of some of the new molecularly targeted agents. Sorafenib was demonstrated to significantly increase the survival of patients with advanced HCC in two prospective, randomized, placebo-controlled trials. Subsequently, a number of retrospective or prospective studies have indicated that the effectiveness of sorafenib therapy in the treatment of HCC is similar in elderly and non-elderly patients. The aim of this review is to describe the impact of age on the effects of sorafenib-targeted therapy in patients with HCC, and the next treatment options with new targeted agents (everolimus, tivantinib, linifanib, etc.).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424–32.

    Article  PubMed  CAS  Google Scholar 

  3. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.

    Article  PubMed  Google Scholar 

  4. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  5. Cho SJ, Yoon JH, Hwang SS, et al. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol. 2007;22:1226–31.

    Article  PubMed  Google Scholar 

  6. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 1999;85:2132–7.

    Article  PubMed  CAS  Google Scholar 

  7. Repetto L, Venturino A, Fratino L, et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer. 2003;39:870–80.

    Article  PubMed  CAS  Google Scholar 

  8. Fentiman IS, Tirelli U, Monfardini S, et al. Cancer in the elderly: why so badly treated? Lancet. 1990;335:1020–2.

    Article  PubMed  CAS  Google Scholar 

  9. Hutchins LF, Unger JM, Crowley JJ, et al. Un-derrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.

    Article  PubMed  CAS  Google Scholar 

  10. Unger JM, Coltman CA Jr, Crowley JJ, et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. Clin Oncol. 2006;24:141–4.

    Article  Google Scholar 

  11. Collier JD, Curless R, Bassendine MF, et al. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing. 1994;23:22–7.

    Article  PubMed  CAS  Google Scholar 

  12. Giannini E, Romagnoli P, Fasoli A, et al. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age Ageing. 2002;31:457–62.

    Article  PubMed  Google Scholar 

  13. Dohmen K, Shirahama M, Shigematsu H, et al. Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19:859–65.

    Article  PubMed  Google Scholar 

  14. Poon RT, Fan ST, Lo CM, et al. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol. 1999;94:2460–6.

    Article  PubMed  CAS  Google Scholar 

  15. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-Hepatobiliary Cancers, Version 1. 2011. http://www.nccn.org/professionals/physician_gls/pdf/.hepatobiliary.pdf. Accessed 3 June 2011.

  16. Di Maio M, De Maio E, Perrone F, et al. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 2002;35:S109–14.

    Article  PubMed  Google Scholar 

  17. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 1999;135:97–105.

    Article  PubMed  CAS  Google Scholar 

  18. Kato A, Miyazaki M, Ambiru S, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol. 2001;78:110–5.

    Article  PubMed  CAS  Google Scholar 

  19. Kuo MT, Zhao JY, Teeter LD, et al. Activation of multidrug resistance (Pglycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ. 1992;3:531–40.

    PubMed  CAS  Google Scholar 

  20. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–8.

    Article  PubMed  CAS  Google Scholar 

  21. Tomizawa M, Shinozaki F, Sugiyama T, et al. Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media. Exp Ther Med. 2010;1(5):863–6.

    Article  PubMed  CAS  Google Scholar 

  22. Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  PubMed  CAS  Google Scholar 

  23. Cheng A, Kang Y, Chen Z. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008;26; abstr 4509.

    Google Scholar 

  24. Wong H, Cheung TT, Fong Tang Y, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011;16:1721–8.

    Article  PubMed  CAS  Google Scholar 

  25. Kim YJ, Jang BK, Kim ES, et al. Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years. J Korean Med Sci. 2012;27:1147–54.

    Article  PubMed  Google Scholar 

  26. Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011;41:296–302.

    Article  PubMed  CAS  Google Scholar 

  27. Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013;30(1):446.

    Article  PubMed  Google Scholar 

  28. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol. 2008;14:1–14.

    Article  PubMed  Google Scholar 

  29. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.

    Article  PubMed  CAS  Google Scholar 

  30. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol. 2004;57:867–71.

    Article  PubMed  CAS  Google Scholar 

  31. Miura H, Miyazaki T, Kuroda M, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997;27:854–61.

    Article  PubMed  CAS  Google Scholar 

  32. Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68–77.

    Article  PubMed  CAS  Google Scholar 

  33. Yamaguchi R, Yano H, Nakashima Y, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 2000;7:725–72.

    PubMed  CAS  Google Scholar 

  34. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003;10:355–62.

    Article  PubMed  Google Scholar 

  35. Jeng KS, Sheen IS, Wang YC, et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol. 2004;10:643–8.

    PubMed  CAS  Google Scholar 

  36. Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354–60.

    Article  PubMed  CAS  Google Scholar 

  37. Hainsworth JD, Burris HA 3rd, Yardley Da, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie PearlCancer Research Network phase II trial. J Clin Oncol. 2001;19:3500–3505.

    Google Scholar 

  38. Del Mastro L, Perrone F, Repetto L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol. 2005;16:253–8.

    Article  PubMed  Google Scholar 

  39. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66–72.

    Article  Google Scholar 

  40. Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer. 2000;27:75–80.

    Article  PubMed  CAS  Google Scholar 

  41. Gridelli C, Cigolari S, Gallo C, et al. Activity toxicity of gemcitabine and gemcitabine plus vinorelbinen in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001;31:277–84.

    Article  PubMed  CAS  Google Scholar 

  42. Nakamura Y, Sekine I, Furuse K, et al. Retro-spective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol. 2000;46:114–8.

    Article  PubMed  CAS  Google Scholar 

  43. Sandler A, Gray R, Perry MC, et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med. 2006;355:2542–50.

    Article  PubMed  CAS  Google Scholar 

  44. Ebi N, Semba H, Tokunaga SJ, et al. A phase II of gefitinib monotherapy in chemotherapynaive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:1166–71.

    Article  PubMed  Google Scholar 

  45. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients <70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–6.

    Article  PubMed  CAS  Google Scholar 

  46. Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100:1454–63.

    Article  PubMed  CAS  Google Scholar 

  47. Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41:1178–9.

    Article  PubMed  CAS  Google Scholar 

  48. Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15:6250–7.

    Article  PubMed  CAS  Google Scholar 

  49. Nichols WW, Nicolini FA, Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl. 1992;10:S73–7.

    Article  PubMed  CAS  Google Scholar 

  50. Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997;96:308–15.

    Article  PubMed  CAS  Google Scholar 

  51. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res. 2009;15:5947–9.

    Article  PubMed  CAS  Google Scholar 

  52. Boehm S, Rothermundt C, Hess D, et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly—a mini-review. Gerontology. 2010;56:303–9.

    Article  PubMed  CAS  Google Scholar 

  53. Qi Y, Dy GK, Nelson D, et al. Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): an analysis of North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol. 2010;28(15 suppl):e18093.

    Google Scholar 

Download references

Acknowledgments

No funding was received for the preparation of this manuscript.

Dr. B Daniele has received consulting and lecture fees from Bayer, Daiichi Sankyo and Novartis. Drs. E Barletta, L Cannella, D Germano and V Tinessa have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Oncology Unit, “G. Rummo” Hospital, Via dell’Angelo, 1, 82100, Benevento, Italy

    D. Germano, V. Tinessa, E. Barletta, L. Cannella & B. Daniele

Authors
  1. D. Germano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Tinessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Barletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Cannella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Daniele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Daniele.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Germano, D., Tinessa, V., Barletta, E. et al. Targeted Therapy for Advanced Hepatocellular Cancer in the Elderly: Focus on Sorafenib. Drugs Aging 30, 887–892 (2013). https://doi.org/10.1007/s40266-013-0124-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0124-6

Keywords

Search

Navigation